Eli Lilly said it would invest $3 billion to expand a recently acquired manufacturing facility to meet growing demand for its diabetes and weight-loss medicines. The drugmaker said the Kenosha County, ...

DealBook Summit, Lilly CEO David Ricks said GLP-1 drugs have the potential to treat more than obesity — including heart disease and substance use disorders.

Eli Lilly said it would invest $3 billion to expand a recently acquired manufacturing facility to meet growing demand for its diabetes and weight-loss medicines.

(Reuters) - Eli Lilly said on Thursday it will invest $3 billion to expand the manufacturing plant it bought in Pleasant ...

Lilly’s blockbuster weight-loss and diabetes drugs have made it the most valuable pharmaceutical company in the world.

STAT reporters Helen Branswell and Allison DeAngelis give updates, respectively, on bird flu and radiopharmaceuticals.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Amgen will raise its biomanufacturing investment in Holly Springs, NC, to $1.5 billion by establishing a second drug ...

Danish drug maker Novo Nordisk said on Thursday it will reduce the U.S. list prices of two insulin products by more than 70% ...

Viking Therapeutics shows strong data with VK2735, a potential competitor to major drugs. Discover why VKTX stock is a ...

Wall Street is chewing over data on Amgen’s weight loss injection, MariTde. Meanwhile, GE HealthCare will acquire a Japanese ...

The jump in prescription fills comes despite limited insurance coverage and high out-of-pocket costs for Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound.